Lupin Limited (LUPIN) Financial Results — Revenue ₹27,958 Cr

StockFin.ai Try Free →

Revenue: ₹27,958 Cr

📢 Key Event
Lupin Limited reported FY26 record revenue of ₹27,958 crores, up 23% YoY, with EBITDA at ₹8,160 crores and 29.7% margin.

🔄 What Changed
23% YoY revenue growth, 55% YoY EBITDA growth, 29.7% EBITDA margin, 40% U.S. sales growth, 7.5% R&D spend as % of sales.

🔮 What's Next
High-single-digit revenue growth and ~25% EBITDA margin guidance for FY27.

💡 Investor Takeaway
Strong top-line growth and margin expansion position Lupin for sustained U.S. revenue leadership despite FY28 competition risks.

Lupin Limited reported record FY26 revenue of **₹27,958 crores**, up 23% YoY, driven by 40% growth in U.S. sales and strong performance across India and emerging markets, with EBITDA surging 55% to **₹8,160 crores** and margins expanding to 29.7%. The company launched key products including Ravicti® and biosimilars, invested 7.5% of sales in R&D, and outlined a strategic focus on doubling complex products in the U.S. and expanding biosimilars, targeting high-single-digit revenue growth and ~25% margins in FY27 amid competitive pressures.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Lupin Limited (LUPIN) — Financial Results Announcement

About Lupin Limited (LUPIN)

Recent Announcements from Lupin Limited